Pancreatic Cancer

News Pancreatic Cancer

• MagForce starts research project with University of Bremen

  MagForce AG announced the start of a research project with the University of Bremen, Center for Environmental Research and Sustainable Technology, for the development of magnetic iron oxid particles with improved efficiency. The novel particles will allow a more efficient treatment of abdominal canc more

• Abraxane plus gemcitabine improves survival in phase III study of patients with advanced pancreatic cancer

  Specialised Therapeutics Australia announced that a phase III clinical trial of breast cancer drug ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with current standard of care gemcitabine in patients with advanced pancreatic cancer has demonstrated substantially improved survival t more

• Clavis Pharma announces negative outcome of pivotal LEAP Trial with CP-4126 in Patients with Metastatic Pancreatic Cancer

  Clavis Pharma ASA announced results of the LEAP (Low hENT1 and Adenocarcinoma of the Pancreas) study of CP-4126 (also known as CO-101), versus gemcitabine in metastatic pancreatic cancer. The trial, which was conducted by partner Clovis Oncology, Inc., showed that there was no difference in overall more

Publications Pancreatic Cancer

• Occurrence of free deaminoneuraminic acid (KDN)-containing complex-type N-glycans in human prostate cancers

  We previously reported on the accumulation of a substantial amount of free N-acetylneuraminic acid (Neu5Ac)-containing complex-type N-glycans in human pancreatic cancer cells (Yabu M, Korekane H, Takahashi H, Ohigashi H, Ishikawa O, Miyamoto Y. 2013. Accumulation of free Neu5Ac-containing complex-t more

• Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial

  Ueda A, Hosokawa A, Ogawa K, Yoshita H, Ando T, Kajiura S, Fujinami H, Kawai K, Nishikawa J, Tajiri K, Minemura M, Sugiyama T more

• Tumor treating fields: a new frontier in cancer therapy

  Tumor treating fields (TTFields) is a noninvasive, regional antimitotic treatment modality that has been approved for the treatment of recurrent glioblastoma by the U.S. FDA and has a CE mark in Europe. TTFields therapy delivers low‐intensity (1–3 V/cm), intermediate‐frequency (100–300 kHz), alter more

Market studies Pancreatic Cancer

• Pancreatic Cancer – Pipeline Review, H1 2012

  Introduction Global Markets Direct’s, 'Pancreatic Cancer - Pipeline Review, H1 2012', provides an overview of the Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Pancreatic Cancer, complete with latest updates, and special features on lat more

• Metastatic Pancreatic Cancer – Pipeline Review, H2 2012

  Introduction Global Markets Direct’s, 'Metastatic Pancreatic Cancer - Pipeline Review, H2 2012', provides an overview of the Metastatic Pancreatic Cancer therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Pancreatic Cancer, complete with latest upd more

• Metastatic Pancreatic Cancer Global Clinical Trials Review, H1, 2012

  Introduction GlobalData's clinical trial report, “Metastatic Pancreatic Cancer Global Clinical Trials Review, H1, 2012" provides data on the Metastatic Pancreatic Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metastatic Pancre more

Websites Pancreatic Cancer